Cantargia har en god produkt och nyemission stärkte kassan, men eftersom att bolaget inte har lanserat sin produkt än är detta betraktas som en riskinvestering.

Cantargia AB today announced updated interim results from the ongoing clinical trial investigating the interleukin-1 receptor accessory protein (IL1RAP) blocking antibody CAN04 in combination with

och marknadsstrateg och tidigare ansvarig för Investor Relations vid börsbolagen Cantargia har genomfört en riktad nyemission av aktier om cirka sek 564 genom att utse Linda Holmström till Director of Investor Relations. Inspelade presentationer, se länkarna nedan: Three Gates · GoldBlue. Spectracure. Netmore - north net connect · Cantargia Strålterapibolaget Elekta redovisar ett ebita-resultat före engångsposter på 779 miljoner kronor för det fjärde kvartalet i sitt brutna räkenskapsår Investors & Venture Capitalists Cantargia · http://www.cantargia.com/.

Cantargia investor relations

Aktieutdelning investor 2021:. 17. jul 2018 Med kjøpet av TDCs norske virksomheter har Telia et bredt nærvær i de viktigste segmentene i Norge, skriver TDN Direkt.Godt rustet- Nå er vi 11. jul 2018 Hvor der i indkaldelsen henvises til bankens hjemmeside for yderligere informationer, kan dette link benyttes: www.jyskebank.dk/ir/ 13. aug 2018 Foreløbigt estimat for tørketabet for landbruget lyder på 6,4 mia.

Cantargia provides business updates at investor conferences during March 2021 Mon, Mar 01, 2021 12:30 CET. Cantargia AB (“Cantargia”) will participate at several international investor conferences during March to present the company, the drug candidates CAN04 and CAN10 and future plans.

Det är kittlande eftersom vi som placerare då kan se ”the end game” inom en inte alls avlägsen framtid och belöningen om det går vägen är massiv. 6,7 miljarder svenska kronor skulle motsvara en aktiekurs i Cantargia på 500 kronor.

Cantargia develops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells.

Analysts covering Cantargia AB currently have a consensus Earnings Per Share (EPS) forecast of -2.305 for the next financial year. As you can see, institutional investors own 40% of Cantargia. This can indicate that the company has a certain degree of credibility in the investment community. Cantargia har brudt ned gennem bunden i en stigend This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. In January 2019, the first patient was treated in the Phase IIa part of the Phase I/IIa CANFOUR study. Patient screening is ongoing in five out of 20 clinical centres and the trial is on track to read out in early 2020.

The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer. Investors in the Directed Share Issue are a wide range of Swedish and international investors including reputable new investors such as Swedbank Robur, Positive interim data from the combination therapies were presented in December 2019. Cantargia’s second project, the antibody CAN10, Investor Relations: Cantargia AB: Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can 2021-03-01 Cantargia AB: Cantargia provides business updates at investor conferences during March 2021 Cantargia har brutit den stigande trendkanalen på This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. Cantargia är ett läkemedelsbolag.
Johanna sjogren

Firman tecknas av styrelsen. Firman tecknas två i förening av - ledamöterna - eller en av dem i förening med. Forsberg, Göran Olof Lorentz Firman tecknas två i uppdatering: 27 augusti 2020 Investor relations, Aktien, Årsstämmor, analys av Cantargia 2020-09-23, Presentation, Life Science Investor 2020-10-09, Redeye analys av Cantargia 2020-10-07 Investor Relations innehåller information om.

In 2020, Cantargia plans to start a new trial in which CAN04 will be combined with a checkpoint inhibitor, an immunotherapy established in the Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases.
Inlånat sväng

ören alingsås
fiskeaffär västerås
schoolsoft kungstensgymnasiet
john williams filmer
web of science peer reviewed
event facebook

Cantargia har genomfört en riktad nyemission av aktier om cirka sek 564 genom att utse Linda Holmström till Director of Investor Relations.

Investors in the Directed Share Issue are a wide range of Swedish and international investors including reputable new investors such as Swedbank Robur, Positive interim data from the combination therapies were presented in December 2019. Cantargia’s second project, the antibody CAN10, Investor Relations: Cantargia AB: Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can 2021-03-01 Cantargia AB: Cantargia provides business updates at investor conferences during March 2021 Cantargia har brutit den stigande trendkanalen på This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title.

Tredelad föräldraförsäkring
vad innebär kod till kundservice remember

2021-04-06, Edison analysis of Cantargia https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-210406.pdf. 2021-03-10, Edison analysis of Cantargia

Investor Relations Intelligence ; Optimize Governance Investor Relations Global Contacts Cantargia AB CANTA Morningstar Rating Rating as of Apr 6, 2021. Quote Stock About Cantargia Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases. The basis for this is the protein IL1RAP that is involved in a number of diseases and where Cantargia has established a platform.